Aflibercept

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Aflibercept and local guidelines before prescribing.

Anti-VEGF agent

Mechanism

VEGF trap given by intravitreal injection.

Uses

Neovascular age-related macular degeneration, diabetic macular oedema, retinal vein occlusion.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Eye pain, conjunctival haemorrhage, raised intraocular pressure, endophthalmitis (rare).

Interactions

None significant systemically.

Contraindications and cautions

Active ocular infection

Monitoring

Visual acuity, intraocular pressure

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

No adjustment

Overdose and reversal

Supportive

Special advice

Intravitreal injection by ophthalmology; report eye pain or visual loss promptly.

More from the textbook: uses, cautions and other points
Where it is discussed in the book